A consensus statement developed by the Pan American League of Associations for Rheumatology (PANLAR) regarding biosimilars warned against the use of so-called "biomimics," or copy biologics.
A consensus statement developed by the Pan American League of Associations for Rheumatology (PANLAR) regarding biosimilars warned against the use of so-called biomimics, or copy biologics.
These products are local copies of approved biologic drugs that received approval without adhering to the international standards for evaluation and approval of biosimilars; the statement said such copies of etanercept and rituximab are available in some Asian and Latin American countries.
If these copies are to be sold, the statement said, they must first be evaluated and approved by a regulatory agency according to guidelines developed by the World Health Organization for new biologics and biosimilars.
The statement was developed through a literature review and a consensus was reached when there was agreement among 80% or more of the panel members. The review included 108 articles, which were classified into the following topics: extrapolation of indications, safety, regulation, interchangeability, pharmacovigilance, immunogenicity, and pharmacoeconomic.
Besides the warning about biomimics, the statement noted the following:
However, no consensus was achieved regarding extrapolation of indications, or about automatic substitution at the pharmacy counter without the permission of the provider.
Among the questions that must be settled, the statement said, are what would be required to designate a drug as interchangeable and how many switches between reference products and biosimilars would be needed in a clinical trial.
Reference
Kowalski, SC, Benavides, JA, Roa, PAB et al. PANLAR Consensus Statement on Biosimilars. Clin Rheumatol. 2019;38(5):1485-1496. doi: 10.1007/s10067-019-04496-3.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Real-World Study: No Increase in Health Resource Costs After Infliximab Biosimilar Introduction
July 20th 2024Although biosimilars reduce drug purchasing costs for hospitals, it’s unclear whether those savings might be offset by increased health resource utilization following a non-medical switching initiative.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.